• Japanese
  • Korean
  • Chinese
Cover Image

Viral Partnering Terms and Agreements

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in viral partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Viral partnering agreement structure
  • Viral partnering contract documents
  • Top viral deals by value
  • Most active viral dealmakers

Description

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual viral deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of viral dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading viral deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of viral deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all viral deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all viral partnering deals signed and announced since 2009. The chapter is organized by specific viral therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all viral partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in viral partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral technologies and products.

Report scope

Viral Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to viral trends and structure of deals entered into by leading companies worldwide.

Viral Partnering Terms and Agreements includes:

  • Trends in viral dealmaking in the biopharma industry since 2009
  • Analysis of viral deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of viral deal contract documents
  • Comprehensive access to over 1,500 viral deal records
  • The leading viral deals by value since 2009
  • Most active viral dealmakers since 2009

In Viral Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Viral Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 viral deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise viral rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Viral Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of viral deal trends since 2009
  • Access infectives deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between viral partner companies
  • Comprehensive access to over 1,500 links to actual viral deals entered into by the world's biopharma companies
  • Indepth review of viral deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner viral opportunities
  • Uncover companies actively partnering viral opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral dealmaking

  • 2.1. Introduction
  • 2.2. Viral partnering over the years
  • 2.3. Bigpharma viral dealmaking activity
  • 2.4. Bigpharma not active in viral
  • 2.5. Viral partnering by deal type
  • 2.6. Viral partnering by industry sector
  • 2.7. Viral partnering by stage of development
  • 2.8. Viral partnering by technology type
  • 2.9. Viral partnering by infectives indication
  • 2.10. Average deal terms for viral
    • 2.10.1 Viral headline values
    • 2.10.2 Viral upfront payments
    • 2.10.3 Viral milestone payments
    • 2.10.4 Viral royalty rates

Chapter 3 - Leading viral deals

  • 3.1. Introduction
  • 3.2. Top viral deals by value
  • 3.3. Top viral deals involving bigpharma

Chapter 4 - Bigpharma viral deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma viral partnering company profiles
  • Abbott
  • Actavis
  • Actelion
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • Galderma
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Purdue
  • Roche
  • Sanofi
  • Servier
  • Shionogi
  • Shire
  • Takeda
  • Teva
  • UCB
  • Valeant
  • Warner Chilcott
  • Watson

Chapter 5 - Viral partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Contract service
  • Co-promotion
  • Development
  • Distribution
  • Equity purchase
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Sub-license
  • Supply
  • 5.3. By stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • 5.4. By technology type
  • Antibodies
  • Assays
  • Biodefense
  • Bioinformatics
  • Biological compounds
  • Biomaterials
  • Cell culture
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Enabling technology
  • Equipment
  • Genomics
  • Industrial chemicals
  • Peptides
  • Proteomics
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Vaccines

Chapter 6 - Viral dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
  • Viral
  • Common cold
  • Cytomegalovirus
  • Ebola
  • FIV
  • Foot and mouth disease
  • Hepatitis
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Herpes simplex
  • HIV
  • Influenza
  • H1N1 (Swine Flu)
  • H5N1 (Avian Flu)
  • Japanese encephalitis
  • Polio
  • Respiratory syncytial virus (RSV)

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Appendix
  • Appendix 1 - Directory of viral deals by company A-Z 2009-2014
  • Appendix 2 - Directory of viral deals by deal type 2009-2014
  • Appendix 3 - Directory of viral deals by stage of development 2009-2014
  • Appendix 4 - Directory of viral deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions

Table of figures

  • Figure 1: Viral partnering since 2009
  • Figure 2: Bigpharma - top 50 - viral deals 2009 to 2012
  • Figure 3: Bigpharma viral deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in viral 2009-2014
  • Figure 5: Viral partnering by deal type since 2009
  • Figure 6: Viral partnering by industry sector since 2009
  • Figure 7: Viral partnering by stage of development since 2009
  • Figure 8: Viral partnering by technology type since 2009
  • Figure 9: Viral partnering by infective target since 2009
  • Figure 10: Viral deals with a headline value
  • Figure 11: Viral deal headline value distribution, US$million - discovery stage
  • Figure 12: Viral deal headline value distribution, US$million - preclinical stage
  • Figure 13: Viral deal headline value distribution, US$million - phase I stage
  • Figure 14: Viral deal headline value distribution, US$million - phase II stage
  • Figure 15: Viral deal headline value distribution, US$million - phase III stage
  • Figure 16: Viral deal headline value distribution, US$million - regulatory stage
  • Figure 17: Viral deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2005-2014
  • Figure 19: Viral deals with upfront payment values
  • Figure 20: Viral deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Viral deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Viral deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Viral deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Viral deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Viral deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Viral deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2005-2014
  • Figure 28: Viral deals with milestone payments
  • Figure 29: Viral deal milestone distribution, US$million - discovery stage
  • Figure 30: Viral deal milestone distribution, US$million - preclinical stage
  • Figure 31: Viral deal milestone distribution, US$million - phase I stage
  • Figure 32: Viral deal milestone distribution, US$million - phase II stage
  • Figure 33: Viral deal milestone distribution, US$million - phase III stage
  • Figure 34: Viral deal milestone distribution, US$million - regulatory stage
  • Figure 35: Viral deal milestone distribution, US$million - marketed stage
  • Figure 36: Viral deals with royalty rates, %
  • Figure 37: Viral deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Viral deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Viral deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Viral deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Viral deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Viral deal royalty rate distribution, US$million - regulatory stage
  • Figure 43: Viral deal royalty rate distribution, US$million - marketed stage
  • Figure 44: Summary median royalty rate by stage of development, 2005-2014
  • Figure 45: Top viral deals by value since 2009
  • Figure 46: Top viral deals signed by bigpharma value since 2005
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published